Welcome to the Nutra Pharma blog, Discovery! My name is Neil Roth and I am the President of Designer Diagnostics, which is the medical devices subsidiary of Nutra Pharma. We currently market and sell diagnostic test kits for the rapid identification of Tuberculosis and NonTuberculous Mycobacterium.

As many of you know, Designer Diagnostics presented at the Mahatma Gandhi Institute in India. The conference was a success. While we were there, Svizera, the exclusive provider of diagnostic test kits to the World Health Organization (WHO), agreed in principal to sell our Tuberculosis test kits to the WHO. Just last year, Svizera sold a total of 15 million test kits to the WHO. This is an incredible opportunity for Nutra Pharma and Designer Diagnostics. We are in the process of completing a series of testing for 3rd party validation.

While we wait for our Tuberculosis test kits to finish the extended testing, we have continued to sell our NonTuberculosis Mycobacterium test kits to companies in Europe, South America, and Africa. We are also continuing to expand our presence in India with additional sales.

We are very excited about the initial popularity of our tests over traditional test kits available on the market. As many of you already know, our test kits offer many additional benefits to organizations in 3rd world countries. For instance, our tests don’t require advanced lab configurations and can last in extreme temperatures and without refrigeration.

Please check back soon for continued postings on the Discovery blog.

Neil

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Initial Popularity for Test Kits at Designer Diagnostics", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

               

Comments

No comments yet.

RSS feed for comments on this post.

TrackBack URL

Leave a Comment

Name (required)

Email (will not be published) (required)

Website